Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAndrew KuykendallRSRory M. ShallisJLJeffrey E. Lancet

Discussion

Loading...

Member takes

Overview

Real-world data shows improved outcomes for acute myeloid leukemia in higher risk myelodysplastic syndromes patients receiving venetoclax combination therapy.

Key Points

  • Acute myeloid leukemia transformation rates were lower in patients receiving venetoclax combination therapy, indicating a potential benefit.
  • Response rates for patients receiving venetoclax combination therapy reached 69.1%, compared to 43.2% for monotherapy.
  • Propensity matching score analysis adjusted for baseline characteristics revealed no significant overall survival difference between treatment groups.
  • Molecular biomarkers and subset analyses may guide future clinical trial designs for targeted therapies in myelodysplastic syndromes.

Cite This Study

Kuykendall et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d79ehttps://doi.org/10.1182/blood-2025-2072
View Full Paper
Ask AI
Bookmark
Share